Skip to main content
OpenTrials
Completed

NCT Number: NCT05417464

Evaluation and Validation of Management Strategy for Conductive Disorders After TAVR (EVATAVI)

Considering decrease of major complications and improvement of procedural results, conductive disorders currently remain the main issue after TAVR (Transcatheter aortic valve replacement).

While pacemaker implantation rate was about 10-15%, new onset LBBB (Left bundle branch block) was observed in 30 % of patients after TAVR but resolved at discharge in the majority of them, with less than 20% progressed to complete AV (atrioventricular) block requiring permanent pacing at hospital discharge.

Higher implantation and improvement of the devices were associated with decline of pace maker implantation rate over the years in experienced teams.

While guidelines do not give definite recommendation regarding conductive disorder management and pacemaker indication, a strategy of selective telemetry monitoring (TM) after TAVR according to the risk of conductive disorders may be proposed to limit indication and lenght of stay of intensive care unit admission (ICU), allowing direct admission of lower risk patients in general cardiology ward (GCW) without TM, to decrease the duration of TM when a conductive disorder is stable or regressive and finally to decrease the rate of pacemakers implantation.

Potential benefit may also include limitation of ICU overload in high volume TAVR centers, investigators can also expect shorter hospitalization duration, with potential economic impact, in line with the development of algorithms for fast track procedures.

Therefore the main objective of our prospective study was to evaluate feasibility and safety of a strategy of management of conductive disorders after TAVR based on an algorithm of diagnosis, monitoring and therapeutic strategies based on ECG analysis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Valvular Heart Disease Aortic Valve Disease Aortic Valve Stenosis Cardiovascular Diseases Heart Diseases Heart Valve Diseases Ventricular Outflow Obstruction

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Hospital

Montpellier, France, 34295

About this study

TAVR is now the reference method for the treatment of severe aortic stenosis in the elderly population. Regarding its good results, indications have recently been extended to younger, lower-risk patients. With the decrease in serious complications, severe conductive disorders requiring the implantation of a pacemaker have thus become the main complications of TAVR.

Despite the experience of operators and modified implantation techniques and in absence of specific recommendations, the rate of pacemaker implantation after a TAVR procedure levels off between 10% and 20% regardless of the prosthesis used and with highly variable rates depending on the center.

In the vast majoriy of cases, the conductive disorders only justify the monitoring of patients in ICU after the procedure,

However, majority of conductive disorders will be regressive or stable and will not justify a permanent pacemaker implantation. Furthemore, this systematic monitoring contributes to unnecessarily overcrowding of these medical structures.

Investigators thus put forward the hypothesis that by using a defined strategy for screening and monitoring conductive disorders occurring after a TAVR procedure, and by taking into account the recommendations on indication of definitive cardiac pacing, it would be possible to rationalize both the indications, the duration of monitoring (by telemetry/CICU or conventional sector) and the definitive pacemaker indication.

Investigators thus hope, thanks to this rationalized strategy, to reduce the indications and durations of monitoring by telemetry or CICU after a TAVR and to shorten the durations of overall hospitalization, but also to reduce the indication for permanent cardiac pacing without risk for the patient.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Any patient who benefits from femoral TAVR regardless of the type of valve.
  • Age ≥ 18 years old.

Exclusion criteria

  • Patients who require CICU monitoring for a reason other than conduction disorders
  • Patients with pacemaker or defibrillator
  • Pregnant or breastfeeding women
  • Patient refusing or unable to give consent: patient under guardianship or curator, mentally retarded, dementia, language barrier
  • Patient not affiliated with an SS scheme
  • Patient under judicial protection

Treatment and study plan

Use of flowchart

Other

Use of flowchart for screening, monitoring and management of conductive disorders after TAVR

Primary outcomes

  1. Occurrence of a serious conductive disorder

    Time frame: Between inclusion and 1 month after TAVR procedure

    Occurrence of a serious conductive disorder (one among the following : syncope, malaise, sudden death, heart failure) outside the CICU (whether the patient was there admitted initially or not)

  2. Occurrence of a serious conductive disorder requiring specific management

    Time frame: Between inclusion and 1 month after TAVR procedure

    Occurrence of a serious conductive disorder requiring specific management (one among the following : drug treatment, need for a transient or permanent pacemaker), outside the CICU (whether the patient was there admitted initially or not)

Secondary outcomes

  1. Incidence and type of conductive disorders requiring transfer to CICU (cardiac intensive care unit)

    Time frame: Between inclusion and 1 month after TAVR procedure

  2. Pourcentage of Pacemaker implantation

    Time frame: Between inclusion and 1 month after TAVR procedure

  3. Time of onset of conductive disorders requiring a pacemaker (immediate, hospital phase, after discharge from hospital)

    Time frame: Between inclusion and 1 month after TAVR procedure

  4. Description of the evolution of conductive disorders that have not been the subject of pacemaker insertion (hospitalization)

    Time frame: Between inclusion and 1 month after TAVR procedure

    Number of conductive disorders that lead to patient's rehospitalization

  5. Description of the evolution of conductive disorders that have not been the subject of pacemaker insertion (death)

    Time frame: Between inclusion and 1 month after TAVR procedure

    Number of conductive disorders that lead to patient's death

  6. Death

    Time frame: Between inclusion and 1 month after TAVR procedure

  7. Clinical status at one month (NYHA (New York Heart Association)

    Time frame: Between inclusion and 1 month after TAVR procedure

  8. Death within the first month after TAVR

    Time frame: Between inclusion and 1 month after TAVR procedure

  9. Duration of hospitalization in CICU

    Time frame: Between inclusion and 1 month after TAVR procedure

  10. Duration of hospitalization in sector

    Time frame: Between inclusion and 1 month after TAVR procedure

Sponsors and collaborators

Lead sponsor

University Hospital, Montpellier

Other

Registry information

Official study title

Evaluation and Validation of a Monitoring, Screening and Management Strategy for Conductive Disorders After TAVR (EVATAVI)

Acronym: EVATAVI

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Jun 14, 2022
Registry last updated
Jun 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.